Skip to content

By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.

Peter Attia MDPeter Attia MD

416 ‒ The science of mitochondria: their role in health, aging, disease, and much more

In this episode, Peter welcomes back Nav Chandel, a Distinguished Professor and world-renowned expert in mitochondrial biology.

Peter AttiahostNav Chandelguest
Nov 16, 20262h 18mWatch on YouTube

Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.

Great conversations run long. Their best ideas don't have to.

uListen is free on iPhone, iPad, Android, Chrome, and Claude.

See how

CHAPTERS

Jump to publisher timestamps

Chapter summaries

  1. What mitochondria do beyond “powerhouse”: ATP, biosynthesis, and cellular decision-making

    Peter Attia and Nav Chandel set the groundwork by reframing mitochondria as more than ATP generators. Nav emphasizes mitochondria’s dual role in energy production and producing metabolites for building cellular components, then introduces a third major role: signaling that influences cell behavior and fate.

    • •Mitochondria are commonly reduced to ATP production, but that model is incomplete
    • •The TCA (Krebs) cycle supports anabolic needs by supplying building blocks for lipids, nucleotides, and amino acids
    • •Mitochondria participate in cellular decision-making and communication, not just “support” functions
    • •Why “mitochondrial dysfunction” as a buzzword requires defining “mitochondrial function” first
  2. Mitochondrial density, supply vs. demand, and why Nav focuses on signaling over “more mitochondria”

    Peter asks about which cells lack mitochondria and how many mitochondria exist per cell, then pivots to whether mitochondrial density tracks energy vs. precursor needs. Nav agrees with the basic framing but explains why he no longer centers his thinking on mitochondrial quantity, because signaling functions complicate the simple supply–demand model.

    • •Red blood cells are identified as lacking mitochondria
    • •Mitochondrial abundance varies by tissue; hepatocytes are described as “full of them”
    • •Peter contrasts ATP-heavy cells with anabolic-heavy cells (e.g., liver)
    • •Nav argues signaling roles may be fulfilled without focusing on mitochondrial biogenesis or counts
  3. Electron transport “leak,” ROS formation, and why hydrogen peroxide isn’t just damage

    Nav explains how electron flow through the electron transport chain can “leak,” producing superoxide and hydrogen peroxide. He and Peter clarify how this differs from the normal endpoint of electron transfer (water), and Nav challenges the view that aging necessarily increases leakiness or toxic ROS generation.

    • •Electron transport is imperfect and can generate superoxide and then H2O2
    • •Peter prompts a biochemistry walkthrough from glucose/pyruvate to NADH and complex I
    • •Nav uses a “waterfall/tank with holes” analogy for electron leak and backpressure
    • •Nav states he does not think normal aging inherently makes the system leakier or creates toxic H2O2 levels
  4. Antioxidant systems, ferroptosis risk, and why supplementation trials have disappointed

    Nav defines antioxidants as protein systems that detoxify reactive oxygen species and explains the enzymatic pathways that handle superoxide and hydrogen peroxide. The discussion moves to when ROS becomes harmful (e.g., via hydroxyl radicals and lipid peroxides leading to ferroptosis) and why antioxidant supplementation trials have largely failed or even backfired.

    • •Antioxidant defenses include superoxide dismutase, catalase, and peroxiredoxins
    • •H2O2 can contribute to hydroxyl radical formation and lipid peroxidation under certain conditions
    • •Nav links lipid peroxides and iron chemistry to ferroptosis
    • •Peter asks why antioxidant supplementation trials fail; Nav answers mostly due to adequate baseline systems and interference with useful signaling
    • •Selenium is discussed as important for GPX4 activity and detoxifying lipid peroxides
  5. Mitochondrial signaling via metabolites: acetyl-CoA, alpha-ketoglutarate, epigenetics, and vitamin C as cofactor

    Nav expands mitochondrial signaling beyond ROS by describing how TCA-cycle metabolites influence protein and histone modifications. He highlights acetyl-CoA in acetylation and alpha-ketoglutarate’s role as a required substrate for a large class of enzymes involved in DNA/histone demethylation and collagen-related processes, with vitamin C needed to keep those enzymes functional.

    • •Acetyl-CoA levels link mitochondria to protein and histone acetylation
    • •Alpha-ketoglutarate supports many enzymes (described as a large class) involved in demethylation and other reactions
    • •Vitamin C is described as necessary to recycle iron and enable alpha-ketoglutarate-dependent enzymes
    • •Nav frames these pathways as mitochondrial control of epigenetic regulation rather than ATP production
  6. Mitochondrial DNA/RNA as immune triggers and the unresolved question of chronic leakage

    Nav explains that mitochondria contain their own DNA/RNA and that release of this genetic material can activate immune sensors normally used for pathogens, generating cytokine signaling. The conversation explores whether low-level chronic release could contribute to long-term inflammation with age, while emphasizing how unclear the release mechanism remains.

    • •Mitochondrial DNA/RNA release can activate immune pathways and type I interferon signaling
    • •Peter probes whether this is an evolved amplification mechanism during infection; Nav cites viral studies where mtDNA release occurs
    • •Nav describes the release mechanism as a “black box,” with hypotheses including mitophagy and fission/fusion issues
    • •The idea of chronic low-level leakage as a contributor to long-term inflammation is presented as a hypothesis
  7. Cytochrome c release, apoptosis, and the possibility of “partial” release for stress signaling

    Nav introduces cytochrome c release as a major mammalian death signal and discusses how this discovery shifted thinking about mitochondria as signaling organelles. He notes emerging arguments that small, non-binary releases might trigger stress signaling without full cell death, paralleling questions about mtDNA leakage.

    • •Cytochrome c release is described as the dominant apoptosis-triggering signal in mammals
    • •Nav connects this classic pathway to broader mitochondrial signaling concepts
    • •The discussion raises uncertainty about whether release events must be binary (organelle/cell death) or can be partial and repairable
    • •Nav notes more discovery is needed to reconcile leakage theories with classic apoptosis mechanisms
  8. Surviving without mitochondrial ATP: glycolytic compensation, AMPK–mTOR signaling, and functional loss

    Peter argues that interrupting mitochondrial ATP production should be incompatible with life, and Nav pushes back with genetic experiments showing cells and even organs can survive for months using glycolysis. They discuss how signaling pathways like AMPK and mTOR changes may allow survival but lead to loss of specialized function and maladaptive remodeling.

    • •Nav describes genetic ETC disruption experiments where cells survive on glycolysis for extended periods
    • •Examples include heart function persisting for months with later hypertrophy and failure
    • •Dopaminergic neurons can survive for months but lose dopamine production before dying
    • •AMPK activation and mTOR suppression are presented as key adaptive signaling responses
  9. Can we measure mitochondrial function? Biopsy limits, “excess capacity,” and lactate-threshold testing as a proxy

    Peter asks for practical tests of mitochondrial function, and Nav says he has none without biopsy-based lab work. They discuss why many measures are hard to interpret due to large mitochondrial reserve capacity and the difference between static metabolite levels and functional flux; Peter proposes lactate-threshold testing during exercise as a pragmatic proxy for oxidative capacity.

    • •Nav says meaningful assessment generally requires tissue biopsy and lab assays (metabolomics, isolated mitochondria tests)
    • •Nav emphasizes substantial excess capacity; large losses may be required before dysfunction becomes obvious
    • •Peter outlines a bike/treadmill test using work output while keeping lactate below a threshold as a proxy for mitochondrial capacity
    • •They distinguish mitochondrial extraction from oxygen delivery factors (heart, blood flow, hemoglobin)
  10. Does mitochondrial dysfunction drive normal aging? Skepticism, “sufficient vs necessary,” and a shift toward signaling defects

    Peter asks whether mitochondrial dysfunction is an inevitable hallmark of aging, and Nav says he is skeptical for healthy individuals. Nav explains that many hallmark arguments are “sufficiency experiments,” and argues that if mitochondria contribute to aging, it may be via nuanced signaling changes (e.g., altered H2O2 signaling, metabolite shifts, or immune activation) rather than ATP collapse.

    • •Nav distinguishes disease states from normal aging in evaluating mitochondrial dysfunction claims
    • •He frames hallmarks evidence as showing sufficiency, not necessity
    • •He describes mouse models where mitochondrial DNA mutation burdens must be far higher than normal aging to produce degeneration
    • •Nav suggests aging-relevant effects may involve miscommunication/signaling rather than ATP or metabolite shortages
  11. Metformin pharmacology and mechanism: gut accumulation, transporters, and complex I inhibition

    Peter pivots to metformin, and Nav explains its distribution and the importance of organic cation transporters for uptake. Nav describes evidence supporting complex I inhibition as a central mechanism—especially in the gut—and discusses downstream metabolic signals and metabolites influenced by metformin exposure.

    • •Metformin concentrates most in the gut, with much lower levels reaching liver and blood
    • •Uptake depends on organic cation transporters; distribution constraints affect which tissues see meaningful exposure
    • •Nav describes experimental use of a yeast complex I bypass (NDI1) showing metformin effects depend on complex I inhibition
    • •Metformin-associated changes discussed include increases in certain signals from the gut and a noted drop in citrulline
  12. Metformin and performance concerns: citrulline, B12, and why muscle effects may be indirect

    Nav and Peter discuss reports that metformin may blunt exercise-related adaptations and explore plausible upstream explanations. Nav highlights citrulline reduction and B12 lowering as gut-linked effects that could influence circulation and mitochondrial function indirectly, while noting that the existing VO2 max data are limited.

    • •Nav connects gut complex I inhibition to reduced intestinal ATP and decreased citrulline production
    • •They discuss a hypothesis that lower citrulline could impair nitric oxide-related vasodilation and oxygen delivery
    • •Metformin-associated B12 reduction is noted, along with possible downstream metabolic consequences
    • •They emphasize uncertainty about direct metformin accumulation in muscle and interpret performance data as modest and short-term
  13. Metformin as a geroprotective? Glucose spikes, ITP results, and what evidence would change minds

    Peter presses on whether metformin benefits insulin-sensitive people for aging, and Nav focuses on post-meal glucose spikes and potential anti-inflammatory effects. They compare metformin to other glucose-regulating drugs tested in the ITP, note metformin’s lack of lifespan extension there, and discuss what better human studies might include.

    • •Metformin is discussed as reducing postprandial glucose spikes when taken before meals
    • •Peter contrasts metformin’s ITP result with acarbose and canagliflozin, which did extend lifespan in that program
    • •They debate what endpoints and monitoring (e.g., glucose monitoring, inflammatory markers) would clarify benefits
    • •Both remain uncertain about routine use in insulin-sensitive individuals
  14. Metformin and cancer: why many trials fail, transporter dependence, and using FDG-PET as a functional stratifier

    Nav explains why metformin’s anti-cancer effects can be inconsistent: efficacy depends on tumor uptake via organic cation transporters and sufficient mitochondrial accumulation to inhibit complex I. He describes experiments where restoring complex I function via NDI1 reverses metformin’s tumor effects, and proposes ways trials could better stratify patients by tumor responsiveness.

    • •Nav describes tumor experiments where metformin shrinks tumors unless complex I inhibition is bypassed by NDI1
    • •A CRISPR screen identified loss of an organic cation transporter as a route to metformin resistance
    • •They discuss the possibility that many tumors may lack transporter expression and thus fail to respond
    • •Nav proposes using changes in FDG-PET glucose uptake after metformin as a way to identify responsive tumors
  15. Inflammation, pollution, viral infections, and clonal hematopoiesis: metformin’s emerging anti-inflammatory use cases

    Nav shifts to inflammation as a reason he personally considers metformin, describing studies where pollution exposure increases mitochondrial ROS signaling and inflammatory cytokines. He also discusses animal studies of viral infections and highlights epidemiologic and mechanistic evidence linking metformin to lower clonal hematopoiesis, including experiments tying the effect to complex I inhibition.

    • •Pollution exposure is discussed as driving IL-6 via mitochondrial H2O2 signaling in macrophages, with metformin lowering IL-6 in animal experiments
    • •Nav cites mouse-model signals suggesting metformin can reduce pathology in viral infection models
    • •Clonal hematopoiesis is defined and linked to age-related inflammatory and cardiovascular risk
    • •Nav describes large-scale observational signals and mouse-model findings where metformin decreases clonal hematopoiesis in a complex I–dependent way
  16. Skepticism of consumer “mitochondrial tests,” plus a reset on cancer metabolism and the Warburg effect

    Peter asks about commercial tests claiming to measure mitochondrial function, and Nav says he’s unaware of any credible non-biopsy approach that yields actionable insight. They then return to cancer biology, clarifying that most cancers have intact mitochondria and that the Warburg effect reflects metabolic strategy for growth rather than respiratory “injury.”

    • •Nav expresses strong doubt that blood/breath-based consumer tests can validly measure mitochondrial function in a meaningful way
    • •He argues steady-state metabolite levels don’t reveal flux or causal interpretation
    • •They clarify that most cancers retain intact electron transport and TCA cycle capacity
    • •The Warburg effect is framed as real but commonly misinterpreted in causality
  17. Mitochondrial supplements tour: urolithin, berberine, alpha-ketoglutarate, CoQ10, NAD precursors, SS-31, methylene blue

    Peter and Nav evaluate popular supplements and “mitochondria boosters,” repeatedly returning to Nav’s framework: where does it go, what is the target, and is there strong human evidence? Nav raises mechanistic concerns for urolithin (conjugation and unclear target), argues berberine appears to act like metformin in his lab’s work, sees alpha-ketoglutarate as mechanistically plausible but potentially niche, and expresses skepticism about broad claims for several others.

    • •Urolithin: Nav emphasizes low unconjugated plasma levels, conjugation issues, and unclear molecular target despite some suggestive studies
    • •Berberine: Nav says his data suggest it lowers glucose via a metformin-like, complex I–linked mechanism
    • •Alpha-ketoglutarate: Nav likes the biology (many enzyme targets) but questions whether it’s rate-limiting and predicts niche indications
    • •CoQ10 and NAD precursors: discussed as potentially useful in specific settings but not clearly geroprotective for most people
    • •SS-31 and methylene blue: Nav questions broad use, cites mechanism uncertainty and safety/therapeutic window concerns
  18. Oxygen interventions and red light therapy: hyperoxia risks, limited value of hypoxia, and cytochrome oxidase hypotheses

    Nav argues against hyperbaric oxygen for general longevity, citing harmful effects of high oxygen exposure in experimental systems and limiting its value to established clinical uses like wound healing. They discuss low-oxygen adaptations (HIF biology) while warning about risks, then explore red light therapy’s proposed interaction with cytochrome c oxidase and possible metabolic effects, emphasizing the need for definitive mechanism tests.

    • •Nav discourages hyperbaric oxygen for longevity, describing high-oxygen exposure as linked to lung senescence and cell death in experimental models
    • •Low oxygen activates known sensing pathways (HIF), but Nav does not endorse hypoxia as a general longevity therapy and notes risks like pulmonary edema at altitude
    • •Red light therapy is discussed as potentially acting via cytochrome c oxidase or nitric oxide interactions, but mechanism remains uncertain
    • •Peter mentions a study showing reduced glucose AUC after red light exposure; they speculate on possible metabolic explanations while emphasizing uncertainty
  19. Why basic metabolism research needs a “moonshot”: funding, incentives, and reforming biomedical research

    Nav closes with a call to scale up investment in metabolism research, arguing it has lagged behind genomics despite its relevance to major diseases and environmental exposures. He also argues academia needs structural reform—greater efficiency and less centralization—while advocating for substantially increased funding from government, philanthropy, and biotech together.

    • •Nav contrasts the scale of the Human Genome Project with the absence of an equivalent effort in metabolism
    • •He argues many toxins and disease processes intersect with mitochondrial and metabolic biology
    • •He calls for increased biomedical research funding paired with changes to academia’s operating model
    • •Nav references a published reform-oriented white paper and notes little has changed since its release

Publisher timestamps

  1. 0:00Intro
  2. 0:11Mitochondrial function: energy production, cellular building blocks, and signaling beyond the powerhouse model
  3. 7:09Electron transport and reactive oxygen species: how mitochondrial energy production creates cellular signaling byproducts
  4. 10:43Oxidative stress and aging: defining antioxidants and antioxidant systems, and the limits of supplementation
  5. 18:42Mitochondrial signaling: metabolites, epigenetic regulation, and immune activation beyond ATP
  6. 23:48How mitochondrial DNA and RNA can activate immune pathways and whether chronic low-level leakage contributes to long-term inflammation and aging
  7. 28:18How mitochondrial release of cytochrome c can trigger cell death or stress signaling
  8. 29:35Mitochondrial dysfunction: survival without mitochondrial ATP production, glycolytic compensation, and the central role of cellular signaling
  9. 34:10How to assess one’s mitochondrial function
  10. 41:48The role of VO2 max and mitochondrial efficiency in maximizing your marginal decade
  11. 47:52Mitochondrial dysfunction and aging
  12. 54:57Metformin mechanisms: gut accumulation, complex I inhibition, and indirect effects on metabolism and exercise
  13. 1:07:50Metformin and aging: does metformin provide true geroprotective benefits beyond glucose control?
  14. 1:12:48Metformin and cancer: why most cancer trials have failed, and how its efficacy depends on tumor-specific uptake
  15. 1:25:25How pollution and viral infections trigger inflammation, and the potential role of metformin as therapy
  16. 1:29:34Clonal hematopoiesis, inflammation, and mitochondrial metabolism: metformin’s role in limiting age-related immune dysregulation
  17. 1:31:51Takeaways on the benefits and risks of using metformin as a geroprotective drug
  18. 1:38:23Views on tests that claim to measure mitochondrial function
  19. 1:41:01The Warburg effect and cancer metabolism: why Nav doesn’t think mitochondria in cancer cells are dysfunctional
  20. 1:43:36Mitochondrial supplements: urolithin A and berberine
  21. 1:52:28Mitochondrial supplements: α-ketoglutarate
  22. 1:55:05Mitochondrial supplements: citrulline, carnitine, CoQ10, NR, and NMN
  23. 1:58:10Interventions touted to boost mitochondrial health: SS-31 and methylene blue
  24. 2:02:31Hyperbaric oxygen and low-oxygen therapy: any real benefits for health and longevity?
  25. 2:07:21Red light therapy: exploring its effects on mitochondria via cytochrome c oxidase and whether purported benefits have a real basis
  26. 2:11:50The case for funding basic research to understand metabolism

Get more out of YouTube videos.

Read along on your phone, search it beside the video, or ask your favorite AI app what was said.